Product Overview
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.
Retatrutide enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists.
Retatrutide is a GGG tri-agonist that targets GLP-1 and GIP receptors, akin to standard GLP-1 agonists, but also uniquely activates the glucagon receptor. This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists.
A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively.
*PRODUCT USAGE: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals/ This product is not a drug, food or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.